文献速递妇科肿瘤

印度9-14岁女孩和男孩接种新型四价HPV疫苗与15-26岁女性接种已上市四价HPV疫苗的免疫原性和安全性比较:一项随机、阳性对照、多中心2/3期试验

Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
PubMed 文献 · Lancet Oncol · 2023-11-07

在印度12家三级医院开展的随机、阳性对照2/3期试验中,9-14岁女孩和男孩接种SIIPL四价HPV疫苗后的抗体GMT相比15-26岁女性接种对照疫苗非劣效,安全性可接受。

要点

  • 9-14岁女孩和男孩接种SIIPL四价HPV疫苗后的GMT相比15-26岁女性接种对照疫苗达到非劣效。
  • SIIPL疫苗组女孩48%、男孩34%发生征集性不良事件,对照疫苗组女孩49%,无3-4级征集性不良事件。
  • 未报告疫苗相关严重不良事件和治疗相关死亡。

核心结论

  • 9-14岁女孩和男孩接种SIIPL四价HPV疫苗的免疫应答相比15-26岁女性接种对照疫苗非劣效,安全性可接受。
  • 作者认为这些发现支持将对照疫苗的效力外推至SIIPL四价HPV疫苗用于较年轻人群。

研究设计与样本

  • 随机、阳性对照、多中心2/3期试验,在印度12家三级医院开展。
  • 2018年9月20日至2021年2月9日筛查2341人,入组并接种2307名无HPV疫苗接种史的健康参与者:9-14岁队列1107人(738名女孩和369名男孩),15-26岁队列1200人(819名女性和381名男性)。
  • 女性参与者按1:1随机分配接受SIIPL四价HPV疫苗(Cervavac)或对照四价HPV疫苗(Gardasil),男性参与者以开放标签方式接种SIIPL四价HPV疫苗。
  • 9-14岁队列采用两剂程序(第0天和第6个月),15-26岁队列采用三剂程序(第0天、第2个月和第6个月),均肌肉注射。
  • 主要终点分析采用改良符合方案人群:SIIPL疫苗组350名女孩和349名男孩,对照疫苗组338名女性。

主要发现

  • 女孩的GMT比值:HPV 6型1.97(98.75%CI 1.67-2.32),11型1.63(1.38-1.91),16型1.90(1.60-2.25),18型2.16(1.79-2.61)。
  • 男孩的GMT比值:HPV 6型1.86(1.57-2.21),11型1.46(1.23-1.73),16型1.62(1.36-1.94),18型1.80(1.48-2.18)。
  • 安全性人群中,SIIPL疫苗组女孩176/369(48%)和男孩124/369(34%)发生征集性不良事件,对照疫苗组女孩179/369(49%)。
  • SIIPL疫苗组女孩143/369(39%)和男孩147/369(40%)发生非征集性不良事件,对照疫苗组女孩143/369(39%)。
  • SIIPL疫苗组3名(1%)女孩和3名(1%)男孩、对照疫苗组5名(1%)女孩发生严重不良事件,未报告疫苗相关严重不良事件和治疗相关死亡。

关键数值与推荐

  • 非劣效界值:GMT比值98.75%CI下限≥0.67。
  • 9-14岁女孩和男孩接种SIIPL四价HPV疫苗相比15-26岁女性接种对照疫苗,针对HPV 6、11、16、18型的GMT比值均达到非劣效。
  • SIIPL疫苗组女孩和男孩以及对照疫苗组女孩均未发生接种后7天内的3-4级征集性不良事件。
  • 最常见的3级非征集性不良事件为登革热:SIIPL疫苗组1名(<1%)女孩,对照疫苗组3名(1%)女孩。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To meet global cervical cancer elimination efforts, a wider range of affordable and accessible vaccines against human papillomavirus (HPV) are needed. We aimed to evaluate the immunogenicity and safety of a quadrivalent HPV vaccine (targeting HPV types 6, 11, 16, and 18), developed and manufactured by the Serum Institute of India (SIIPL). Here we report outcomes in the 9-14 years cohort. METHODS: This randomised, active-controlled, phase 2/3 trial was conducted at 12 tertiary care hospitals across India. Healthy participants aged 9-14 years or 15-26 years with no history of HPV vaccination were eligible for enrolment. Female participants were randomly assigned (1:1) with an interactive web response system, by use of a central computer-generated schedule and block randomisation (block sizes of 2, 4, 6, and 8), to receive the SIIPL quadrivalent HPV vaccine (Cervavac; SIIPL, Pune, India) or the comparator quadrivalent HPV vaccine (Gardasil; Merck Sharp & Dohme, Harleem, the Netherlands). Participants, investigators, laboratory technicians, and sponsors were masked to treatment allocation of female participants. Male participants were given the SIIPL quadrivalent HPV vaccine in an open-label manner. Study vaccines were administered intramuscularly with a two-dose schedule (at day 0 and 6 months) in the cohort aged 9-14 years, and with a three-dose schedule (at day 0, month 2, and month 6) in the cohort aged 15-26-years. Immunogenicity was assessed 30 days after the last dose by use of multiplexed ELISA. The primary outcome was the non-inferiority of immune response in terms of the geometric mean titre (GMT) of antibodies against HPV types 6, 11, 16, and 18 generated by the SIIPL quadrivalent HPV vaccine in girls and boys (aged 9-14 years) compared with the GMT generated by the comparator quadrivalent HPV vaccine in women aged 15-26 years at month 7 in the modified per-protocol population (ie, all participants who received all doses of study vaccines per assigned treatment group and had both day 0 and 1-month immunogenicity measurements after the last dose following protocol-defined window periods with no major protocol deviations). Non-inferiority was established if the lower bound of the 98·75% CI of the GMT ratio was 0·67 or higher. The co-primary outcome of occurrence of solicited adverse events (within 7 days of each dose) and unsolicited adverse events (up to 30 days after the last dose) was assessed in all participants who were enrolled and received at least one dose of study vaccine. The trial is registered with the Clinical Trials Registry - India (CTRI/2018/06/014601), and long-term follow-up is ongoing. FINDINGS: Between Sept 20, 2018, and Feb 9, 2021, 2341 individuals were screened, of whom 2307 eligible individuals were enrolled and vaccinated: 1107 (738 girls and 369 boys) in the cohort aged 9-14 years and 1200 (819 women and 381 men) in the cohort aged 15-26 years. No race or ethnicity data were collected. 350 girls and 349 boys in the SIIPL quadrivalent HPV vaccine group and 338 women in the comparator vaccine group were included in the modified per-protocol population for the primary endpoint analysis. The median follow-up for the analyses was 221 days (IQR 215-231) for girls and 222 days (217-230) for boys in the SIIPL quadrivalent HPV vaccine group, 223 days (216-232) for girls in the comparator vaccine group, and 222 days (216-230) for women in the comparator vaccine group. GMT ratios were non-inferior in girls and boys receiving the SIIPL quadrivalent HPV vaccine compared with women receiving the comparator vaccine: GMT ratios for girls were 1·97 (98·75% CI 1·67-2·32) for HPV type 6, 1·63 (1·38-1·91) for HPV type 11, 1·90 (1·60-2·25) for HPV type 16, and 2·16 (1·79-2·61) for HPV type 18. For boys the GMT ratios were 1·86 (1·57-2·21) for HPV type 6, 1·46 (1·23-1·73) for HPV type 11, 1·62 (1·36-1·94) for HPV type 16, and 1·80 (1·48-2·18) for HPV type 18. The safety population comprised all 1107 participants (369 girls and 369 boys in the SIIPL quadrivalent HPV vaccine group, and 369 girls in the comparator group). Solicited adverse events occurred in 176 (48%) of 369 girls and 124 (34%) of 369 boys in the SIIPL vaccine group and 179 (49%) of 369 girls in the comparator vaccine group. No grade 3-4 solicited adverse events occurred within 7 days of each dose. Unsolicited adverse events occurred in 143 (39%) girls and 147 (40%) boys in the SIIPL vaccine group, and 143 (39%) girls in the comparator vaccine group. The most common grade 3 unsolicited adverse event was dengue fever, in one (<1%) girl in the SIIPL vaccine group and three (1%) girls in the comparator group. There were no grade 4 or 5 adverse events. Serious adverse events occurred in three (1%) girls and three (1%) boys in the SIIPL vaccine group, and five (1%) girls in the comparator vaccine group. No vaccine-related serious adverse events were reported. There were no treatment-related deaths. INTERPRETATION: We observed a non-inferior immune response with the SIIPL quadrivalent HPV vaccine in girls and boys aged 9-14 years and an acceptable safety profile compared with the comparator vaccine. These findings support extrapolation of efficacy from the comparator vaccine to the SIIPL quadrivalent HPV vaccine in the younger population. The availability of the SIIPL quadrivalent HPV vaccine could help meet the global demand for HPV vaccines, and boost coverage for both girls and boys globally. FUNDING: Biotechnology Industry Research Assistance Council, Department of Biotechnology (DBT), Government of India, and Serum Institute of India.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Sharma H, Parekh S, Pujari P, et al. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. Lancet Oncol. 2023. PMID: 37949086. doi:10.1016/S1470-2045(23)00480-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。